Trial intelligence / Profile preview

NANT Pancreatic Cancer Vaccine in Advanced Pancreatic Cancer

NCT03586869Phase 2

Key facts

Status: Terminated
Start: Jul 2018
Primary completion: Apr 2019
Countries: 1
Sponsor: ImmunityBio, Inc.
Modality: Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines

Drugs: aldoxorubicinnogapendekin alfa inbakicepthaNKETBX-011ETBX-021
Conditions: pancreatic adenocarcinoma (PDAC)

Overview

Phase 2, open-label, single-arm trial of aldoxorubicin, nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021 and 5 more in pancreatic adenocarcinoma (PDAC), sponsored by ImmunityBio, Inc. Primary endpoint: Treatment-emergent Adverse Events and Serious Adverse Events up to 230 days. Started Jul 2018; status: terminated.

Design

1 arm

Study design: Non-randomizedOpen-label

NANT Pancreatic Cancer Vaccine
Combination of Aldoxorubicin, Anktiva, haNK, multiple Ad5 and Yeast vaccines, plus chemo/immunotherapy backbone

Endpoints

Primary

Treatment-emergent Adverse Events and Serious Adverse EventsUp to 230 days

Secondary

Objective Response RateUp to 6.8 months
Progression Free SurvivalUp to 6.8 months
Overall SurvivalFrom screening to death
Duration of ResponseUp to 6.8 months
Disease Control RateUp to 6.8 months
Quality of LifeUp to 12.7 months

Beyond the preview

Go deeper on NCT03586869.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03586869.